According to the
FDA said that the affected applications from Ranbaxy are for drugs that fall into three categories: Approved drugs made at the Paonta Sahib site for the
To address the falsified data, the FDA has invoked its Application Integrity Policy (AIP) against the Paonta Sahib facility. The AIP is invoked when a company's actions raise significant questions about the integrity of data in drug applications. The AIP covers applications that rely on data generated by the Paonta Sahib facility only.
crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1735.45 |
Dr. Reddys Lab | 1144.05 |
Cipla | 1441.70 |
Lupin | 2026.50 |
Zydus Lifesciences | 885.70 |
View more.. |